Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › GPCR

Structure Therapeutics

GPCR Rare disease Lead: Phase 3 4 Biotech Distilled articles ↓ 17 filings & releases ↓ Cash $273M (Jun 30, 2026) ↓ 4 verdicts ↓ 4 timing quotes ↓
MetabolicRespiratory Small Molecule

Market cap $4.35B 213.9M shares (10-Q, Jul 31, 2026) × $20.35 close Nov 6, 2026

Most recent annual filing: 2026-02-26

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. aleniglipron Ph2 topline4Q 2026aleniglipron Ph2 topline, 4Q 2026, major
  2. ACCG-3535 / combination trial Ph14Q 2026ACCG-3535 / combination trial Ph1, 4Q 2026, notable
  3. ACCG-2671 Ph1 readout1H 2027ACCG-2671 Ph1 readout, 1H 2027, material

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (5 active programs)

Technology platforms

Structure-Based Drug Discovery Platform · Schrödinger

GPCR-focused structure-based drug discovery platform combining 3D protein structure visualization, computational chemistry, and physics-based methods in collaboration with Schrödinger. Targets GPCRs in metabolic, cardiovascular, and pulmonary diseases, enabling design of oral small molecule therapeutics against targets historically limited to peptides or biologics.

Targets: GPCRs

GPCR Structure-Based Drug Discovery

Structure-based drug discovery and computational chemistry platform focused on G-protein coupled receptors (GPCRs); targets metabolic, cardiovascular, pulmonary and neurological disorders including obesity, T2DM, MASH, heart failure, sleep apnea, chronic kidney disease, and osteoarthritis.

Targets: GIPR, GCGR, GLP-1R

Discontinued (1)

Capital (as filed)

Cash
$273M cash and cash equivalents · Jun 30, 2026 (10-Q)
Short-term investments
$1.07B Jun 30, 2026
Operating cash flow
−$120M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$1.34B cash per the update of Sep 8, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on Structure Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-04-28 Buy core Structure Therapeutics (GPCR) - Scientific Deep Dive for Aleniglipron and Pipeline Products Small molecule oral GLP-1 agonist with best-in-class Phase 2b efficacy, clean liver safety, $1.5B war chest removing dilution risk, and exceptionally high M&A appeal as a prime buyout target for Big Pharma seeking to bypass the injectable peptide duopoly.
  2. 2026-05-08 Buy core UPDATE: Structure Therapeutics (GPCR) - The 16.3% Print and the Quiet ATM Upsize Data improved to 16.3% placebo-adjusted weight loss at 180mg and FDA gave clean end-of-Phase-2 guidance, but the ATM uncapping signals management is prepared to fund through Phase 3 independently, adding financing risk to an otherwise stronger thesis.
  3. 2026-08-07 Buy core UPDATE: Structure Therapeutics (GPCR) - Phase 3 Is Dosing, and the Stock Already Knows Phase 3 ACCOMPLISH initiated on schedule with the best-performing dose, FDA alignment confirmed, Nature Medicine publication adds credibility, and a Novo Nordisk obesity commercial chief hired, all validating the original thesis despite rising burn rate and unresolved Phase 3 tolerability at scale.
  4. 2026-09-09 Hold UPDATE: Structure Therapeutics (GPCR) - The Amylin Data Landed, and So Did the Stock Aleniglipron's 72-week durability and improved tolerability remain intact, but the amylin franchise leg is repriced as a 2027 binary question after ACCG-2671 showed universal GI events at the only weight-loss-producing dose, narrowing the modular franchise thesis and extending the catalyst timeline.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (4 quotes from 3 filings)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (17)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 26, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

3 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)